Core Insights - The inclusion of "medical beauty services" in the CPI marks a significant shift for the industry, transitioning from a niche service to a recognized component of the national economic monitoring system [3][19] - The implementation of the new VAT regulations explicitly excludes profit-driven medical beauty institutions from tax exemptions, reinforcing their classification as commercial services and eliminating tax arbitrage opportunities [3][19] - These dual policy adjustments signify a transition from "wild growth" to "regulated development," fundamentally restructuring the competitive landscape and development logic of the medical beauty industry [3][19] Market Dynamics - The medical beauty market is experiencing "differentiated growth," with leading chain institutions achieving growth through refined operations, while smaller institutions face significant operational pressures [5][21] - In the first half of 2025, over 63% of medical beauty institutions reported revenue declines, with only 14% achieving growth; Q2 was particularly challenging, with 58% of institutions experiencing declines [5][21] - The average customer spending in the medical beauty industry dropped to 6,500 yuan, a 10% decrease year-on-year, while the frequency of consumer visits increased, indicating a trend towards more conservative spending among middle and high-income consumers [5][21] Consumer Trends - The trend of "popularization and down-market penetration" is becoming increasingly evident, with lower-tier cities emerging as new growth engines for the industry [6][22] - By 2025, the proportion of medical beauty institutions in third-tier cities and below increased from 30% in 2022 to 42%, with overall consumption growth reaching 22%, double that of first-tier cities [6][22] - Non-surgical light medical beauty projects have become the mainstream, accounting for over 53% of the market, with a market size of 227.9 to 258 billion yuan, driving industry growth [6][22] Regulatory Environment - The simultaneous implementation of the CPI inclusion and new VAT regulations represents a policy "one-two punch" for the regulated development of the medical beauty industry, establishing its commercial consumption attributes [8][24] - This regulatory shift has eliminated the "gray area" label that has long plagued the industry, with the CPI now monitoring price fluctuations and consumption scale as part of national economic management [9][25] - The combination of these policies is transforming the identity of the medical beauty industry from "marginal service" to "mainstream consumption," laying the groundwork for its regulated development [10][26] Competitive Landscape - The regulatory changes are leading to a "good money driving out bad money" scenario, where compliant institutions benefit from favorable conditions while non-compliant ones face significant operational challenges [11][27] - Over 18,000 non-compliant institutions were shut down in 2025, and more than 320 violators had their licenses revoked, indicating the effectiveness of ongoing regulatory measures [11][27] - The market is shifting from a seller's market to a buyer's market, with price wars becoming a primary strategy for smaller institutions competing for customers [6][22] Industry Evolution - The medical beauty industry is transitioning from an upstream-dominated model to one focused on terminal capabilities, with an emphasis on differentiation and scale as core competitive advantages [12][28] - Upstream companies are shifting their focus from licensing to product innovation, as competition intensifies and profit margins normalize [13][29] - The entry of public hospitals into the medical beauty sector is becoming a new variable, with a significant increase in the number of public hospitals establishing medical beauty departments [14][30] Consumer Behavior - Consumers are becoming more rational, shifting from a focus on appearance changes to daily anti-aging maintenance, with increased demands for product safety and institutional compliance [15][31] - This rationalization is driving industry upgrades, as institutions move towards standardized solutions that combine products, medical expertise, and post-operative management [15][31] - The transparency of industry information is improving, allowing consumers to compare the overall value of different institutions, which is pushing prices towards greater fairness [15][31]

Core Insights - The Chinese medical beauty market is experiencing a significant transformation in 2025, marked by a notable divergence in the performance of various brands within the regenerative filling materials sector, with "Zhenai Su Fei" leading with a 463% growth while "Yiyan Shi" saw a 56% decline [1][2] - The market is witnessing a "Matthew Effect," where leading brands are consolidating their positions, while smaller brands struggle to survive [1][10] Regenerative Filling Materials - Regenerative filling materials have become the "MVP" of the year, with a 93.40% increase in sales in 2025, continuing a three-year growth trend [2] - "Zhenai Su Fei" from Aimeike achieved the highest growth rate at 463%, while "Yiyan Shi" faced a significant decline of 56% [2][3] - The performance of "Yiyan Shi" is attributed to its early market entry, but its novelty has worn off, leading to decreased consumer interest [3] Market Dynamics - The market is increasingly competitive, with new brands and materials entering, but consumers tend to prefer established brands for their reliability [4] - The sales of the once-popular ultrasonic device have dropped significantly, with a 55.2% decline in 2025, as consumers are opting for newer products and are more budget-conscious [4][5] Equipment and Technology - The "Meila Meisu" ultrasonic knife has emerged as a leading anti-aging device, with a 147.22% increase in sales, appealing to users over 35 seeking non-invasive treatments [4][5] - The ultrasonic device is transitioning from a "market dividend period" to a "technical barrier period," indicating a shift in competitive dynamics [5][7] Hyaluronic Acid - Hyaluronic acid remains a top-selling product, with a 19.70% increase in sales in 2025, maintaining its status as a staple in the market [8] - Despite its growth, hyaluronic acid faces challenges such as market oversupply and price wars, which could weaken its position in the long term [8][9] Future Growth Areas - The market is shifting towards specialized treatments, with a focus on individual needs and the emergence of new segments like collagen reorganization and hair loss treatment, which are expected to see significant growth [10][11] - The collagen reorganization market is projected to grow at a compound annual growth rate of 41.4% from 2023 to 2027, indicating strong potential [10]

Core Insights - The Chinese medical beauty market is experiencing a significant shift in 2025, marked by a 93.40% growth in the regenerative filling materials sector, but with notable disparities among brands [1][2] - The "Matthew Effect" is becoming evident, where leading brands are gaining market share at the expense of smaller competitors, particularly in the context of regulatory barriers and technological advancements [1][10] Regenerative Filling Materials - Regenerative filling materials have emerged as the "MVP" of the year, with a 93.40% increase in sales in 2025, continuing a trend of rapid growth over the past three years [2] - The brand "Zhenai Su Fei" under Aimeike leads with a remarkable 463% growth, while "Yiyan Shi" from Huadong Pharmaceutical, once a market leader, has seen a 56% decline [2][3] - Despite the growth of "Zhenai Su Fei," its contribution to Aimeike's overall performance remains uncertain, as the company reported over a 20% decline in revenue and net profit in the first three quarters of 2025 [2] Market Dynamics - The decline of "Yiyan Shi" is attributed to its earlier market entry leading to reduced novelty among consumers, and some users seeking alternative products after initial experiences [3] - The market for ultrasonic devices, once a star in anti-aging treatments, has seen a 55.2% drop in sales, indicating a shift in consumer preferences and budget constraints [4][8] - In contrast, the "Meila Meisheng" ultrasonic knife has gained popularity, with a 147.22% increase in sales, appealing to users aged 35 and above [4][5] Competitive Landscape - The competitive landscape is tightening, with head brands further squeezing the market space for smaller brands, as consumers tend to prefer established, reliable products [4] - The decline in ultrasonic device sales is not solely due to the emergence of new technologies but also reflects market misuse and consumer fatigue [7][10] Hyaluronic Acid Market - Hyaluronic acid remains a top-selling product, with a 19.70% increase in sales in 2025, despite facing challenges such as oversupply and intense price competition [8][9] - The product's versatility and ability to cater to a wide range of consumer needs contribute to its sustained popularity, positioning it as a mainstay in the anti-aging market [9] Future Growth Areas - The market is transitioning towards specialized segments, with a focus on individual needs and the emergence of new growth areas such as recombinant collagen products, hair loss treatments, and weight management [10][11] - The recombinant collagen market is projected to grow at a compound annual growth rate of 41.4% from 2023 to 2027, indicating strong potential for expansion [10]

Core Insights - The medical beauty market is experiencing a surge in demand as consumers prepare for the upcoming Spring Festival, with many opting for aesthetic treatments to enhance their appearance [1][3]. Group 1: Market Trends - There has been a significant increase in user visits to medical beauty services, with Meituan reporting over a 15% year-on-year growth and nearly a 10% week-on-week increase [3]. - The demand for aesthetic treatments is primarily focused on anti-aging, wrinkle removal, and urgent skin condition improvement, with varying recovery periods influencing consumer choices [3]. - Popular treatments have shifted from longer recovery options like Thermage and Ultherapy to shorter recovery options such as hyaluronic acid injections and photorejuvenation [3]. Group 2: Company Initiatives - Meituan has launched a "Beautiful New Year" campaign, offering a 3000 yuan medical beauty voucher package and a beauty calendar to help users select appropriate treatments based on recovery times [3]. - During the Spring Festival, at least 30% of medical beauty institutions on the Meituan platform will remain open, which is a 5% increase compared to the previous year, providing convenience for users seeking urgent skin treatments [3]. - The company promotes the "Safe Beauty" initiative to ensure compliance and safety in the industry, aiming to verify over 12 million treatment instances by the end of 2025 across 2500 institutions in 140 cities [4].

Core Insights - The medical beauty market is experiencing a surge in demand as consumers prepare for the upcoming Spring Festival, with many opting for aesthetic treatments to enhance their appearance [1][2]. Group 1: Market Trends - There is a notable shift in consumer behavior, with traditional beauty treatments being supplemented by light medical beauty procedures, forming a new "Spring Festival beauty package" [1]. - Meituan's data indicates a more than 15% year-on-year increase in user visits to medical beauty services, with a nearly 10% week-on-week growth, reflecting heightened market activity [1]. - The demand is primarily focused on anti-aging, wrinkle removal, and skin emergency treatments, with varying popularity based on recovery times [1]. Group 2: Treatment Popularity - Treatments like Thermage and Ultherapy peaked in early January but have seen a gradual decline, while hyaluronic acid, Botox, and photorejuvenation have been on the rise recently [1]. - Meituan has launched a "Beautiful New Year" campaign, offering a 3000 yuan medical beauty voucher package and a beauty calendar to help users choose suitable treatments [1]. Group 3: Operational Insights - During the Spring Festival, at least 30% of medical beauty institutions on the Meituan platform will remain open, an increase of about 5 percentage points from the previous year, providing convenience for users seeking treatments [2]. - Meituan is promoting the "Safe Beauty" initiative to ensure compliance and safety in the industry, aiming to have over 12 million verified treatments by the end of 2025, covering 2500 institutions across 140 cities [3].

Core Insights - The National Healthcare Security Administration (NHSA) is shifting its project establishment guidelines from a focus on technical details to a value-based approach centered on service output [2][3] Group 1: Project Establishment Guidelines - As of now, the NHSA has issued 33 batches of project establishment guidelines, integrating 1,640 main projects, 599 additional items, and 156 expansion items [3] - The new guidelines aim to unify pricing projects across regions, addressing inconsistencies and ensuring comparability in pricing levels [3] - The guidelines emphasize a shift in logic from technical operation details to service output, reflecting the principle that "value determines price" [3] Group 2: Focus on Aesthetic Medicine - The new guidelines standardize 101 main projects in aesthetic medicine at the national level, including procedures like "photonic rejuvenation" and "ultrasound therapy" [4] - While the guidelines aim to meet the growing demand for aesthetic services, they do not alter the market regulation of aesthetic pricing, which remains under the discretion of medical institutions [4] Group 3: Integration of Services - The NHSA is integrating various projects to ensure a unified approach across the country, such as standardizing the "fetal heart monitoring" project to "fetal/instance" [5] - The integration process has led to the consolidation of 271 existing projects into 124 main projects, making the guidelines more accommodating to new technologies [5] - Local healthcare departments are actively implementing the new guidelines, with provinces like Henan and Guangdong restructuring their project classifications and pricing methods [6] Group 4: Future Directions - The NHSA plans to accelerate the development of guidelines for pharmacy, testing, and auxiliary operations, aiming for comprehensive implementation by 2026 [6][7] - The NHSA will continue to focus on new technologies and products, guiding local healthcare authorities in their implementation processes [7]

Core Insights - The National Healthcare Security Administration (NHSA) is shifting its project establishment guidelines from a focus on technical details to a value-based approach centered on service output [2][3] Group 1: Project Establishment Guidelines - As of now, the NHSA has issued 33 batches of project establishment guidelines, integrating 1,640 main projects, 599 additional items, and 156 expansion items [3] - The new guidelines aim to standardize pricing projects across regions, addressing inconsistencies and ensuring comparability in pricing levels [3] - The guidelines emphasize a shift in project establishment logic from operational details to service output, reflecting the principle that "value determines price" [3] Group 2: Focus on Aesthetic Medicine - The new guidelines have unified 101 main projects in aesthetic medicine at the national level, covering procedures like "photorejuvenation," "ultrasound therapy," and "Thermage" [4] - The NHSA emphasizes that while the guidelines standardize projects, the pricing in the aesthetic medicine market will still be determined by medical institutions independently [4] Group 3: Integration of Services - The NHSA is integrating various projects to ensure a unified approach across the country, such as standardizing the "fetal heart monitoring" project to "fetal/instance" [5] - The integration process has reduced 271 existing projects to 124 main projects, allowing for a more granular approach that is more accommodating to new technologies [5] - Local healthcare departments are actively implementing the new guidelines, with provinces like Henan consolidating 54 rehabilitation projects into 17 [5] Group 4: Pricing Clarity and Support for Innovation - The new guidelines are making medical pricing clearer and more aligned with the value of technical services, as seen in Guangdong's reduction of 208 body system projects to 53 [6] - The guidelines have established pricing rules for anesthesia recovery phases, extending service periods to enhance patient safety [6] - The NHSA plans to accelerate the development of guidelines for pharmacy, testing, and auxiliary operations, aiming for comprehensive implementation by 2026 [6]

Core Insights - The National Healthcare Security Administration (NHSA) has issued 33 batches of project guidelines, integrating 1,640 main projects, 599 additional items, and 156 expansion items [1][2] - The guidelines aim to standardize pricing for medical services, addressing issues of price inconsistency and unclear charging boundaries across regions [1][2] - The NHSA emphasizes the relationship between enhancing public health welfare and stabilizing medical institution operations, indicating that both aspects are crucial for pricing and project establishment [2] Group 1: Project Guidelines - The NHSA has focused on merging similar old projects into new standardized projects to resolve inconsistencies in pricing and service outputs [1] - New projects are designed to accommodate diverse clinical treatment scenarios, enhancing the granularity of pricing and allowing for the inclusion of new technologies [1][2] Group 2: Aesthetic Medical Services - The NHSA has established 101 main projects for aesthetic medical services, including popular procedures like "photorejuvenation" and "ultrasound therapy," to meet the growing demand in this sector [2] - The guidelines aim to promote high-quality aesthetic services and guide public medical institutions in setting reasonable prices while maintaining market regulation [2] Group 3: Future Directions - The NHSA plans to accelerate the development of guidelines for pharmacy, testing, and auxiliary operations, aiming for comprehensive implementation by 2026 [3] - Continuous attention will be given to new technologies and products, with guidance for provincial healthcare departments to support innovation in the medical field [3]

Core Viewpoint - The article explores the psychological and financial implications of cosmetic procedures, highlighting the shift from rational decision-making to compulsive behavior in the pursuit of beauty, and the resulting anxiety and dissatisfaction that can arise from such choices [1][19][32]. Group 1: Personal Experience with Cosmetic Procedures - The subject, Xiaoman, has been engaged in cosmetic procedures for six years, starting with a focus on her nose due to childhood trauma [3][4]. - Initially, Xiaoman was rational in her choices, carefully selecting materials and practitioners, and adhering to a budget [7][8]. - The rise of "light medical beauty" has made non-invasive procedures more popular, surpassing traditional surgical options in market value since 2022 [10]. Group 2: Psychological Impact and Behavioral Changes - Xiaoman's experience reflects a broader trend where cosmetic procedures become a coping mechanism for personal crises, leading to excessive spending and a loss of control [13][19]. - After a breakup and increased work stress, Xiaoman's rational approach deteriorated, resulting in impulsive decisions regarding cosmetic treatments, leading to significant financial expenditure [17][18]. - The article discusses the concept of "spiritual essence," suggesting that while individuals may enhance their appearance, they risk losing their unique qualities [21][23]. Group 3: Industry Dynamics and Consumer Behavior - The cosmetic industry has shifted from exploiting information asymmetry to creating a cycle of anxiety and dependency on procedures [27][34]. - Consumers are becoming more informed and discerning, often researching specific treatments and practitioners before making decisions, which has led to a decrease in prices for certain procedures [26]. - The industry's focus on enhancing beauty standards perpetuates a cycle of demand, where individuals feel compelled to continuously invest in their appearance to meet societal expectations [35][36].

Financial Performance - The company reported a significant improvement in operating cash flow, with a year-on-year increase of 300.52% [2] - Revenue from the cardiovascular interventional business reached 1.239 billion, a growth of 7.57% year-on-year [2] - The overall revenue and profit for the first half of the year remained stable compared to the previous year [2] Business Segments Medical Devices - The in vitro diagnostics and surgical anesthesia segments experienced slight declines in revenue due to increased competition and procurement rhythms [2] - The skin care business aims for sales of 500-600 million in 2026, with a net profit margin of 45-50% [3] Innovative Drugs - The innovative drug segment is the largest in terms of R&D investment, focusing on metabolic diseases [4] - The company is optimistic about the potential of its innovative drugs, particularly in weight management and metabolic disorders [4] Strategic Adjustments - The company has undergone organizational restructuring to stabilize its performance after a period of significant fluctuations [2] - Future growth is expected to be driven by strategic emerging business segments, including dermatology and innovative drugs [2] Market Strategy - The company plans to maintain a sales expense ratio below 20% for its medical aesthetics products, focusing on scientific and cost-effective marketing strategies [8] - The pricing strategy for the "童颜针" (youthful needle) series aims to capture a broader market by offering competitive pricing [15] Regulatory and Competitive Landscape - The company anticipates a reduction in prices for drug-coated balloons due to procurement policies, which may increase market penetration [9] - The competitive landscape for GLP-1 drugs is intensifying, but the company remains confident in its product competitiveness [20] Future Outlook - Analysts project a net profit of around 1 billion for the current year, with a stable outlook for the formulation business [2] - The company aims for a revenue growth of 10-15% next year, driven by structural heart disease and pharmaceutical products [2]